Shengshi Tyco was rated as the most growing innovative pharmaceutical enterpriseToday, there is good news from the 6th China Biomedical Innovation Cooperation Conference and the 2022 China biomedical industry value list award ceremony: Shengshi Tyco was selected into the list of "top 10 small molecule innovative drug enterprises with the most growth". In the past month, Shengshi Tyco has successively approved two new drug products under development by both China and the United States, opening a new journey for innovative drugs to go to sea.

The current China Biomedical Innovation Cooperation Conference focuses on cutting-edge technology information, interprets the latest industrial policies, and links industry, University, research, and funding. Among them, Wanyi medicine and China Medical Research Institute made comprehensive judgments from multiple dimensions, such as strategic elements, product elements, competitive elements, team elements, commercialization elements and value elements, and conducted in-depth evaluation on industries, industries and enterprises. After collection, data return visit, systematic research and other evaluation processes, the "2022 China biomedical industry value list" was formed. The list was officially released at the plenary meeting.

Shengshi Tyco was founded in Suzhou Industrial Park in 2010. The core team has decades of experience in the whole life cycle of international drugs, and is committed to the R & D and industrialization of small molecule innovative drugs for breakthrough therapies. Relying on the integrated drug R & D technology platform and diversified business vision, the company has built a rich pipeline of innovative drugs, covering many disease fields such as glucose lowering, anticancer and rare diseases.

Recently, these three layout areas have achieved continuous success. In the field of glucose lowering, shenggliptin phosphate, an original new drug DPP-4 inhibitor, has entered the final stage of phase III clinical treatment, and is expected to fill the gap of domestic original oral glucose lowering drugs; Three of the anticancer drugs under research have entered the clinic. The FGFR / VEGFR dual target inhibitor cgt-6321 has been carried out in phase I clinical trials in advanced solid tumors, and this drug is expected to become a potential first in class drug; CXCR4 antagonist cgt-1881 is used for hematopoietic stem cell mobilization, and oral administration is more convenient; Cgt-9475, a new generation ALK / ret inhibitor, is expected to solve several major clinical pain points such as drug resistance and brain metastasis in the treatment of lung cancer. The first two projects have obtained the clinical license of the US FDA, which is a solid step for the company's innovative drugs to go to sea. In addition, the first domestic copy of the treatment of rare disease multiple sclerosis will be officially launched in the near future, which will benefit domestic patients with high quality and more affordable prices.